|
Genes under-expressed in patients with JRA |
|||||
| GenBank accession no. |
Symbol |
Description |
Avg. control |
Avg. patients |
Ratio C/P |
|
|
|||||
| NM_001145 |
ANG |
Angiogenin, ribonuclease, RNase A family, 5 |
18.8 |
6.1 |
3.1 |
| NM_000041 |
APOE |
Apolipoprotein E |
16.9 |
7.2 |
2.3 |
| NM_002983 |
CCL3 |
chemokine (C-C motif) ligand 3 |
166.7 |
7.4 |
22.4 |
| D90145 |
CCL3L1 |
chemokine (C-C motif) ligand 3-like 1 |
197.7 |
21.4 |
9.2 |
| NM_002984 |
CCL4 |
chemokine (C-C motif) ligand 4 |
221.7 |
22.2 |
10.0 |
| NM_002985 |
CCL5 |
chemokine (C-C motif) ligand 5 |
38.5 |
8.3 |
4.7 |
| NM_001781 |
CD69 |
CD69 antigen (p60, early T-cell activation antigen) |
23.5 |
4.5 |
5.2 |
| NM_004233 |
CD83 |
CD83 antigen (activated B lymphocytes, immunoglobulin superfamily) |
24.3 |
0.1 |
365.9 |
| NM_031226 |
CYP19A1 |
cytochrome P450, family 19, subfamily A, polypeptide 1 |
25.8 |
9.2 |
2.8 |
| NM_004408 |
DNM1 |
Dynamin 1 |
13.6 |
4.1 |
3.3 |
| NM_004418 |
DUSP2 |
Dual specificity phosphatase 2 |
54.1 |
7.8 |
6.9 |
| NM_000114 |
EDN3 |
Endothelin 3 |
36.7 |
11.8 |
3.1 |
| NM_001961 |
EEF2 |
Eukaryotic translation elongation factor 2 |
114.1 |
29.1 |
3.9 |
| NM_005252 |
FOS |
V-fos FBJ murine osteosarcoma viral oncogene homolog |
483.5 |
100.4 |
4.8 |
| NM_006732 |
FOSB |
FBJ murine osteosarcoma viral oncogene homolog B |
89.6 |
11.7 |
7.7 |
| NM_015675 |
GADD45B |
Growth arrest and DNA-damage-inducible, beta |
87.5 |
19.3 |
4.5 |
| NM_012483 |
GNLY |
Granulysin |
47.5 |
2.5 |
19.2 |
| NM_006144 |
GZMA |
Granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) |
15.3 |
4.5 |
3.4 |
| NM_019111 |
HLA-DRA |
Major histocompatibility complex, class II, DR alpha |
226.5 |
33.9 |
6.7 |
| NM_006895 |
HNMT |
Histamine N-methyltransferase |
13.4 |
4.4 |
3.1 |
| NM_031157 |
HNRPA1 |
Heterogeneous nuclear ribonucleoprotein A1 |
31.8 |
8.8 |
3.6 |
| NM_014365 |
HSPB8 |
heat shock 22-kDa protein 8 |
23.8 |
7.0 |
3.4 |
| NM_000576 |
IL1B |
Interleukin 1, beta |
169.0 |
22.4 |
7.5 |
| AK055991 |
LAMR1 |
Laminin receptor 1 (67 kDa, ribosomal protein SA) |
35.3 |
14.2 |
2.5 |
| NM_002305 |
LGALS1 |
Lectin, galactoside-binding, soluble, 1 (galectin 1) |
15.5 |
4.3 |
3.6 |
| X60188 |
MAPK3 |
Mitogen-activated protein kinase 3 |
228.5 |
81.3 |
2.8 |
| NM_020529 |
NFKBIA |
Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha |
705.4 |
56.0 |
12.6 |
| NM_002135 |
NR4A1 |
Nuclear receptor subfamily 4, group A, member 1 |
46.0 |
15.4 |
3.0 |
| NM_006186 |
NR4A2 |
Nuclear receptor subfamily 4, group A, member 2 |
35.7 |
9.5 |
3.8 |
| U12767 |
NR4A3 |
Nuclear receptor subfamily 4, group A, member 3 |
18.3 |
4.4 |
4.2 |
| BC011589 |
OSM |
Oncostatin M |
19.8 |
5.3 |
3.8 |
| NM_002659 |
PLAUR |
Plasminogen activator, urokinase receptor |
23.8 |
4.8 |
4.9 |
| NM_000311 |
PRNP |
Prion protein (p27-30) |
15.0 |
5.1 |
3.0 |
| NM_000963 |
PTGS2 |
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
174.9 |
30.4 |
5.8 |
| NM_002823 |
PTMA |
Prothymosin, alpha (gene sequence 28) |
169.0 |
56.0 |
3.0 |
| NM_000994 |
RPL32 |
Ribosomal protein L32 |
174.4 |
58.6 |
3.0 |
| NM_002966 |
S100A10 |
S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide [p11]) |
33.9 |
9.2 |
3.7 |
| NM_003745 |
SOCS1 |
suppressor of cytokine signaling 1, SSI-1 |
23.1 |
8.2 |
2.8 |
| NM_032298 |
SYT3 |
synaptotagmin III, DKFZp761O132 |
30.2 |
11.4 |
2.7 |
| NM_003246 |
THBS1 |
Thrombospondin 1 |
33.7 |
11.1 |
3.0 |
| NM_006290 |
TNFAIP3 |
Tumour necrosis factor, alpha-induced protein 3 |
112.1 |
24.9 |
4.5 |
| NM_003407 |
ZFP36 |
Zinc finger protein 36, C3H type, homolog (mouse) |
177.8 |
51.5 |
3.5 |
|
Avg. control, average (normalised) intensity in controls; Avg. patients, average (normalised) intensity in patients; Ratio C/P, fold difference between controls and patients. | |||||
Jarvis et al. Arthritis Research & Therapy 2006 8:R154 doi:10.1186/ar2048 |
|||||